Stacie Wilson
Internal Medicine · Saint Louis, MONPI 1902469075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. Reporting peaked in 2022 at $214 and has fallen 91.3% since, to $19 in 2025.
Across 24 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$103
- Lilly USA, LLC$67
- Ironwood Pharmaceuticals, Inc$56
- AstraZeneca$42
- Takeda Pharmaceuticals U.S.A., Inc.$40
- AbbVie$39
- plus $74 from 4 others
What the payments were for
- Food & beverage$420100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 6 | $103 |
| Lilly USA, LLC | 4 | $67 |
| Ironwood Pharmaceuticals, Inc | 3 | $56 |
| AstraZeneca | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| AbbVie | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Amgen | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$420 in reported general payments places this provider in the 60th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 40 | $271 |
| Allopurinol | 16 | $178 |
| Lisinopril | 20 | $159 |
| Simvastatin | 24 | $107 |
| Meloxicam | 11 | $62 |
| Metformin Hcl | 16 | $40 |
| Amlodipine Besylate | 23 | $33 |
| Hydrochlorothiazide | 17 | $30 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.